Ibrahim Azar, MD
@ibrahimazaronc
Medical Oncologist @IHACares Assistant Professor @WayneState. Alum @karmanoscancer @AlbanyMed
@mcgillu. AΩA. GI Oncology Mednet Associate Editor.
ID: 1078622782580248576
28-12-2018 12:04:45
880 Tweet
839 Followers
973 Following
Most viewed in the last 7 days from JAMA Internal Medicine: Clinical Insights by Tim Anderson and @ZacharyGJacobs proposes a new framework for managing asymptomatic blood pressure elevation in the hospital setting. ja.ma/3yqQ64L
Day made thanks to ASCO TECAG ASCO for providing a platform for young trainees at #ASCO24 as we presented our work from Yale Internal Medicine Yale Cancer Center Paul Stockhammer Michael Grant! Fernando Diaz, MD Jacob J. Adashek, DO
Five-year survival in pts with #SCLC treated with first-line carboplatin, etoposide, and atezolizumab (IMpower 133 to IMbrella A extension) Lung Cancer Journal. 3y OS rate 16%, 4y OS 13%, 5y OS 12%. Confirms long-term survival possible for subset of pts. lungcancerjournal.info/article/S0169-…
✍️Mark your calendar for our next upcoming space‼️ Fellowship Application; The Program Director Perspective, with Dr. Rami Manochakian, Heme/onc Fellowship PD at Mayo Clinic FL❗️ 📅 Wednesday, 21st August 2024 ⏰ 7 pm EST Moderator: Noha N. Soror, MD, MSc. 𓂀 🌟Speaker: Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation
Should we get rethink the full (complete) blood count? Burack et al. argue for a change - to get rid of many values & using two streamlined versions of - maintaining the comprehensive count only when clinically indicated. Link to ASH Clinical News article below.
Glad to share our new publication- “Grade 4 adverse bleeding diathesis related to Ibrutinib”. Thanks to the program leadership for the constant support. Geetha Krishnamoorthy Sumeet Yadav @ ASH ISTH HTRSFellows Hemostasis and Thrombosis Research Society
Hot off the press in Annals of Oncology: Is adjuvant ribociclib ready for prime time? Recommended read in preparation for the NATALEE 4y update at #ESMO24 annalsofoncology.org/article/S0923-…